Baader Bank Aktiengesellschaft purchased a new position in shares of Ocugen, Inc. (NASDAQ:OCGN – Free Report) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 22,550 shares of the company’s stock, valued at approximately $35,000.
Several other institutional investors also recently bought and sold shares of OCGN. Truefg LLC purchased a new position in Ocugen during the 1st quarter worth $34,000. David J Yvars Group purchased a new position in Ocugen during the 1st quarter worth $35,000. Headlands Technologies LLC purchased a new position in Ocugen during the 1st quarter worth $66,000. Tidal Investments LLC purchased a new position in Ocugen during the 1st quarter worth $108,000. Finally, State Board of Administration of Florida Retirement System purchased a new position in Ocugen during the 1st quarter worth $132,000. 10.27% of the stock is currently owned by hedge funds and other institutional investors.
Ocugen Stock Up 2.3 %
OCGN stock traded up $0.03 on Thursday, hitting $1.31. 3,266,831 shares of the company’s stock were exchanged, compared to its average volume of 7,147,027. Ocugen, Inc. has a 12-month low of $0.35 and a 12-month high of $2.11. The firm has a 50 day moving average price of $1.52 and a two-hundred day moving average price of $1.37. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.87 and a current ratio of 1.87. The stock has a market cap of $337.13 million, a P/E ratio of -5.12 and a beta of 3.65.
Wall Street Analysts Forecast Growth
OCGN has been the topic of several research reports. HC Wainwright restated a “buy” rating and set a $7.00 price objective on shares of Ocugen in a report on Wednesday, May 15th. Chardan Capital reiterated a “buy” rating and issued a $5.00 price target on shares of Ocugen in a report on Wednesday, May 15th.
Get Our Latest Report on Ocugen
Ocugen Company Profile
Ocugen, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease.
Featured Stories
- Five stocks we like better than Ocugen
- Consumer Discretionary Stocks Explained
- Michael Burry’s Alibaba Bet and the Broader Market Implications
- How to Calculate Options Profits
- Jeff Brown’s Exegesis AI Stock Picks
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- Warren Buffett’s Bet: Why Berkshire Hathaway Bought Ulta Stock
Want to see what other hedge funds are holding OCGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ocugen, Inc. (NASDAQ:OCGN – Free Report).
Receive News & Ratings for Ocugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocugen and related companies with MarketBeat.com's FREE daily email newsletter.